Physician profile
Steven Hwang
NPI 1245735729
$4,287.39
in general payments reported to CMS, 2019-2025
45 companies · $3,420 in 2025
The $3,420 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $867 · 2025: $3,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,287.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $389.74 | 2024-2025 | |
| Janssen Biotech, INC. | $368.20 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Merck Sharp & Dohme LLC | $284.61 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| E.R. Squibb & Sons, L.L.C. | $264.22 | 2024-2025 | Opdivo, Krazati |
| Caris Mpi, INC. | $232.83 | 2025 | Mi Cancer Seek |
| Incyte Corporation | $174.68 | 2024-2025 | Pemazyre, Monjuvi, Jakafi |
| Abbvie INC. | $166.16 | 2024-2025 | |
| Beone Medicines USA, INC. | $158.23 | 2025 | Brukinsa, Tevimbra |
| Astrazeneca Pharmaceuticals LP | $155.35 | 2024-2025 | Calquence, Imfinzi, Lynparza |
| Eisai INC. | $148.59 | 2024-2025 | |
| Pfizer INC. | $109.41 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $107.53 | 2024-2025 | Fruzaqla, Ninlaro |
| Sumitomo Pharma America, INC. | $103.94 | 2024-2025 | Orgovyx |
| Csl Behring | $96.86 | 2024-2025 | Hizentra |
| Beigene USA, INC. | $95.97 | 2024-2025 | Brukinsa, Tevimbra |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $91.19 | 2025 | Cabometyx |
| Celgene Corporation | $85.73 | 2025 | Reblozyl |
| Genentech USA, INC. | $81.50 | 2024-2025 | Tecentriq, Itovebi, Polivy |
| Astellas Pharma US INC | $80.82 | 2024-2025 | Xtandi, Xospata |
| Ipsen Biopharmaceuticals, INC | $79.25 | 2024 | Onivyde, Somatuline Depot |
| Bayer Healthcare Pharmaceuticals INC. | $75.01 | 2024-2025 | |
| Glaxosmithkline, LLC. | $68.98 | 2024-2025 | Ojjaara, Jemperli |
| Sobi, INC | $61.95 | 2024-2025 | |
| Kite Pharma, INC. | $60.13 | 2025 | Yescarta |
| Regeneron Healthcare Solutions, INC. | $59.80 | 2025 | Libtayo |
| Alexion Pharmaceuticals, INC. | $58.94 | 2024-2025 | Ultomiris, Soliris |
| Gilead Sciences, INC. | $50.95 | 2024-2025 | Trodelvy |
| Servier Pharmaceuticals LLC | $49.47 | 2025 | |
| Iovance Biotherapeutics, INC. | $49.35 | 2024-2025 | Amtagvi |
| Genmab U.S., INC. | $47.60 | 2024-2025 | Epkinly |
| Array Biopharma INC | $46.08 | 2025 | Mektovi, Braftovi, Tukysa |
| Genzyme Corporation | $38.39 | 2024-2025 | |
| Adaptive Biotechnologies Corporation | $34.15 | 2024-2025 | Clonoseq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.52 | 2024-2025 | Gilotrif |
| Stemline Therapeutics INC. | $31.22 | 2025 | Orserdu |
| Fennec Pharmaceuticals, INC. | $30.69 | 2025 | Fyarro |
| Daiichi Sankyo INC. | $28.11 | 2025 | Datroway |
| Geron Corporation | $27.99 | 2025 | Rytelo |
| Myriad Genetic Laboratories, INC. | $27.26 | 2024 | Myrisk, Precisetumor |
| Janssen Scientific Affairs, LLC | $25.70 | 2024 | Rybrevant |
| Recordati_rare_diseases_inc. | $24.83 | 2025 | Enjaymo |
| Aveo Pharmaceuticals, INC. | $24.52 | 2025 | |
| Deciphera Pharmaceuticals INC. | $21.99 | 2025 | Romvimza, Qinlock |
| Coherus Oncology, INC. | $19.99 | 2024 | |
| Acrotech Biopharma INC. | $17.96 | 2025 | Beleodaq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Hwang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.